Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC
Por:
Gomez Huelgas, R, Gomez Peralta, F, Carrillo Fernandez, L, Galve, E, Casanueva, F, Puig Domingo, M, Mediavilla Bravo, J, Orozco D, Ena Munoz, J, Menendez Torre, E, Artola Menendez, S, Mazon Ramos, P, Monereo Megias, S, Caixas Pedragos, A, Lopez Simarro, F, Alvarez Guisasola, F and Grp Trabajo Documento Consenso
Publicada:
1 dic 2015
Categoría:
Medicine (miscellaneous)
Resumen:
Obesity and excess weight are the main preventable causes of type 2 diabetes (DM2). When diagnosing type 2 diabetes, clinicians should establish the degree of obesity according to the body mass index (BMI) and, for patients with excess weight, measure the waist circumference. The proper treatment of DM2 requires a simultaneous approach to excess weight/obesity and the other cardiovascular risk factors, such as hypertension, dyslipidaemia and smoking. Nondrug interventions (e.g., diet and exercise) have proven benefits in preventing and treating patients with DM2 and excess weight/obesity and should follow an individual and multidisciplinary approach, with structured programs equipped with specific resources. Weight gain associated with antidiabetic treatment can hinder glycaemic control, compromise treatment adherence, worsen the vascular risk profile and limit the cardiovascular benefits of treatment. Therefore, it is significant to avoid weight gain, a measure that can be cost-effective. Antidiabetic drugs with benefits in body weight have also demonstrated their benefit in patients with BMIs <30. In general, the treatment of patients with DM2 and obesity will depend both on the degree of obesity and the associated comorbidity. Clinical trials on DM2 intervention should consider combined objectives that include not only glycaemic control but also other variables such as the risk of hypoglycaemia and the effect of treatment on body weight. (C) 2015 Elsevier Espana, S.L.U. and Sociedad Espanola de Medicina Interna (SEMI). All rights reserved.
Filiaciones:
Gomez Huelgas, R:
SEMI, Madrid, Spain
Gomez Peralta, F:
SED, Madrid, Spain
Carrillo Fernandez, L:
Red Grp Estudio Diabet Atenc Primaria Salud redGD, Madrid, Spain
Galve, E:
SEC, Madrid, Spain
Casanueva, F:
Soc Espanola Estudio Obesidad SEEDO, Madrid, Spain
Puig Domingo, M:
Soc Espanola Endocrinol & Nutr SEEN, Madrid, Spain
Mediavilla Bravo, J:
Soc Espanola Med Atenc Primaria SEMERGEN, Madrid, Spain
Orozco D:
SEMFYC, Madrid, Spain
Ena Munoz, J:
SEMI, Madrid, Spain
Menendez Torre, E:
SED, Madrid, Spain
Artola Menendez, S:
Red Grp Estudio Diabet Atenc Primaria Salud redGD, Madrid, Spain
Mazon Ramos, P:
SEC, Madrid, Spain
Monereo Megias, S:
Soc Espanola Estudio Obesidad SEEDO, Madrid, Spain
Caixas Pedragos, A:
Soc Espanola Endocrinol & Nutr SEEN, Madrid, Spain
Lopez Simarro, F:
Soc Espanola Med Atenc Primaria SEMERGEN, Madrid, Spain
Alvarez Guisasola, F:
SEMFYC, Madrid, Spain
Open Access
FULL TEXT
 |
Published Version |
This policy does not allow for Open Access for this version |
| No Accesible |
|